Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma
Delord, Jean-Pierre, Robert, Caroline, Nyakas, Marta, McArthur, Grant A, Kudchakar, Ragini, Mahipal, Amit, Yamada, Yasuhide, Sullivan, Ryan, Arance, Ana, Kefford, Richard F, Carlino, Matteo S, Hidalgo, Manuel, Gomez-Roca, Carlos, Michel, Daniela, Seroutou, Abdelkader, Aslanis, Vassilios, Caponigro, Giordano, Stuart, Darrin D, Moutouh-de Parseval, Laure, Demuth, Tim, Dummer, Reinhard
Published in Clinical cancer research (15.09.2017)
Published in Clinical cancer research (15.09.2017)
Get full text
Journal Article
P1024: MYLOX‐1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS
Harrison, Claire, Mascarenhas, John, Cilloni, Daniela, Schlenk, Richard, Jacoby, Brian, Slack, Robert J, Aslanis, Vassilios, Singh, Bhupinder, Lindmark, Bertil, Verstovsek, Srdan, Rampal, Raajit K
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects
Shakeri-Nejad, Kasra, MD, Aslanis, Vassilios, PharmD, Veldandi, Uday Kiran, PhD, Mooney, Louise, PhD, Pezous, Nicole, Brendani, Bruno, Juan, Axel, MD, Allison, Mark, MD, Perry, Robert, MD, Legangneux, Eric, MD
Published in Clinical therapeutics (01.11.2015)
Published in Clinical therapeutics (01.11.2015)
Get full text
Journal Article
Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects
Legangneux, Eric, MD, Shakeri-Nejad, Kasra, MD, Aslanis, Vassilios, PharmD, Sagkriotis, Alexandros, MS, Pezous, Nicole, Brendani, Bruno, Behrje, Rhett, MS, Gutierrez, Maria, MD
Published in Clinical therapeutics (01.03.2016)
Published in Clinical therapeutics (01.03.2016)
Get full text
Journal Article
Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia
Wire, Mary B, Li, Xiaobin, Zhang, Jianping, Sallas, William, Aslanis, Vassilios, Ouatas, Taoufik
Published in Clinical pharmacology and therapeutics (01.12.2018)
Published in Clinical pharmacology and therapeutics (01.12.2018)
Get more information
Journal Article
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects
Aslanis, Vassilios, Umehara, Kenichi, Huth, Felix, Ouatas, Taoufik, Bharathy, Savita, Butler, Andrew Avigdor, Zhou, Wen, Gadbaw, Brian
Published in Cancer chemotherapy and pharmacology (01.10.2019)
Published in Cancer chemotherapy and pharmacology (01.10.2019)
Get full text
Journal Article
Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis
Verstovsek, Srdan, Mascarenhas, John, Rampal, Raajit K, Cilloni, Daniela, Harrison, Claire, Jacoby, Brian, Slack, Robert J., Aslanis, Vassilios, Singh, Bobby, Lindmark, Bertil
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial
Ghiringhelli, François, Doucet, Ludovic, Barre, Patricia, Pichon, Eric, Ponce Aix, Santiago, Juan-Vidal, Oscar, Carcereny, Enric, Sethi, Tariq, Lindmark, Bertil, MacKinnon, Alison, Aslanis, Vassilios, Rajiwate, Zahir, Basse, Linda
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions
Umehara, Kenichi, Huth, Felix, Jin, Yi, Schiller, Hilmar, Aslanis, Vassilios, Heimbach, Tycho, He, Handan
Published in Drug metabolism and drug interactions (30.05.2019)
Published in Drug metabolism and drug interactions (30.05.2019)
Get full text
Journal Article
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)
Gaughan, Erin E, Quinn, Tom M, Mills, Andrew, Bruce, Annya M, Antonelli, Jean, MacKinnon, Alison C, Aslanis, Vassilios, Li, Feng, O'Connor, Richard, Boz, Cecilia, Mills, Ross, Emanuel, Philip, Burgess, Matthew, Rinaldi, Giulia, Valanciute, Asta, Mills, Bethany, Scholefield, Emma, Hardisty, Gareth, Findlay, Emily Gwyer, Parker, Richard A, Norrie, John, Dear, James W, Akram, Ahsan R, Koch, Oliver, Templeton, Kate, Dockrell, David H, Walsh, Timothy S, Partridge, Stephen, Humphries, Duncan, Wang-Jairaj, Jie, Slack, Robert J, Schambye, Hans, Phung, De, Gravelle, Lise, Lindmark, Bertil, Shankar-Hari, Manu, Hirani, Nikhil, Sethi, Tariq, Dhaliwal, Kevin
Published in American journal of respiratory and critical care medicine (15.01.2023)
Published in American journal of respiratory and critical care medicine (15.01.2023)
Get full text
Journal Article
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants
Aslanis, Vassilios, Slack, Robert J., MacKinnon, Alison C., McClinton, Catherine, Tantawi, Susan, Gravelle, Lise, Nilsson, Ulf J., Leffler, Hakon, Brooks, Ashley, Khindri, Sanjeev K., Marshall, Richard P., Pedersen, Anders, Schambye, Hans, Zetterberg, Fredrik
Published in Cancer chemotherapy and pharmacology (01.03.2023)
Published in Cancer chemotherapy and pharmacology (01.03.2023)
Get full text
Journal Article
Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1)
Aslanis, Vassilios, Abd-Elaziz, Khalid, Slack, Robert J., Brinch, Anne, Gravelle, Lise, Morley, Wayne, Phung, De, Herman, Kimberly, Holyer, Ian, Poulsen, Karen Killerup, Dogterom, Peter, Tantawi, Susan, Zetterberg, Fredrik R., Jacoby, Brian, Schambye, Hans, Lindmark, Bertil
Published in Cancer chemotherapy and pharmacology (01.11.2024)
Published in Cancer chemotherapy and pharmacology (01.11.2024)
Get full text
Journal Article
Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment
Aslanis, Vassilios, Gray, Michael, Slack, Robert J., Zetterberg, Fredrik R., Tonev, Dimitar, Phung, De, Smith, Becky, Jacoby, Brian, Schambye, Hans, Krastev, Zahari, Ungell, Anna-Lena, Lindmark, Bertil
Published in Clinical drug investigation (01.10.2024)
Published in Clinical drug investigation (01.10.2024)
Get full text
Journal Article
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
Shakeri-Nejad, Kasra, Aslanis, Vassilios, Veldandi, Uday Kiran, Gardin, Anne, Zaehringer, Andreas, Dodman, Angela, Su, Zhenzhong, Legangneux, Eric
Published in International journal of clinical pharmacology and therapeutics (01.01.2017)
Published in International journal of clinical pharmacology and therapeutics (01.01.2017)
Get full text
Journal Article
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study
Frey, Noelle, Jang, Jun Ho, Szer, Jeff, Illés, Árpád, Kim, Hee-Je, Ram, Ron, Chong, Beng H, Rowe, Jacob M, Borisenkova, Elena, Liesveld, Jane, Winer, Eric S, Cherfi, Azzeddine, Aslanis, Vassilios, Ghaznawi, Farhat, Strickland, Stephen
Published in The Lancet. Haematology (01.03.2019)
Published in The Lancet. Haematology (01.03.2019)
Get more information
Journal Article
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions
Umehara, Kenichi, Huth, Felix, Jin, Yi, Schiller, Hilmar, Aslanis, Vassilios, Heimbach, Tycho, He, Handan
Published in Drug metabolism and personalized therapy (30.05.2019)
Get more information
Published in Drug metabolism and personalized therapy (30.05.2019)
Journal Article
Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
Veldandi, Uday Kiran, Shakeri-Nejad, Kasra, Biswal, Shibadas, Pawar, Atul Keshav, Camm, Alan John, Pal, Parasar, Aslanis, Vassilios, Jordaan, Pierre, Legangneux, Eric, Polus, Florine, Sagkriotis, Alexandros
Year of Publication 02.04.2024
Get full text
Year of Publication 02.04.2024
Patent
TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER
PAL, Parasar, PAWAR, Atul Keshav, POLUS, Florine, LEGANGNEUX, Eric, VELDANDI, Uday Kiran, BISWAL, Shibadas, SAGKRIOTIS, Alexandros, SHAKERI-NEJAD, Kasra, ASLANIS, Vassilios, JORDAAN, Pierre, CAMM, Alan John
Year of Publication 09.11.2023
Get full text
Year of Publication 09.11.2023
Patent
TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER
Veldandi, Uday Kiran, Shakeri-Nejad, Kasra, Biswal, Shibadas, Pawar, Atul Keshav, Camm, Alan John, Pal, Parasar, Aslanis, Vassilios, Jordaan, Pierre, Legangneux, Eric, Polus, Florine, Sagkriotis, Alexandros
Year of Publication 13.01.2022
Get full text
Year of Publication 13.01.2022
Patent